Skip to main content
Premium Trial:

Request an Annual Quote

Theradiag Subsidiary Inks HIV/AIDS Diagnostics Deal with CNRS

NEW YORK (GenomeWeb News) – French molecular diagnostics firm Theradiag announced Monday that its microRNA diagnostics subsidiary Prestizia has inked two deals to develop HIV/AIDS assays in collaboration with the French National Center for Scientific Research (CNRS).

The first agreement relates to a 2013 collaboration between Theradiag, the drug development firm Splicos, and CNRS, which are jointly developing RNA-targeting therapeutics and companion diagnostic tests for HIV/AIDS and obesity. Specifically, Prestizia and CNRS have now agreed to develop an miRNA-based companion diagnostic for Splico's investigational HIV treatment SPL-464, as well as a predictive and monitoring test for the disease.

The second agreement extends an ongoing alliance between Prestizia and CNRS focused on the use of miRNAs as biomarkers of HIV/AIDS tropism to include long non-coding RNAs.

Additional terms of the deals were not disclosed.